This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
VP Research & Development
Is leading BrainsWay’s Research and Product Development departments.
Prior to this, Moria served as head of Biomedical Engineering Department and held the position of Project Management Officer.
Moria brings with her considerable experience and expertise in regulatory affairs, and comprehensive knowledge of brain stimulation technologies in general and of TMS in particular.
Moria holds a BSc. in Biomedical Engineering from the Jerusalem College of technology (JCT) with specializations in electro-optics.
Moria is driven by a passion to advance the development of BrainsWay’s future and existing product line as part of the ever-expanding neurostimulation market.